Avio Smart Market Stack Limited (ASMS) and Huwel Lifesciences have announced the upcoming launch of Cubo, an ultra-compact and cost-effective RT-PCR platform designed to expand access to molecular diagnostics across India and global healthcare systems.

 

Positioned as a first-of-its-kind indigenous innovation, Cubo integrates laboratory-grade RT-PCR capabilities with a highly portable and economical deployment model. The platform is expected to offer both companies a significant early-mover advantage in one of the fastest-growing segments of healthcare technology.

 

Developed as a breakthrough in decentralised healthcare, Cubo enables advanced molecular testing within a compact footprint that can be deployed well beyond traditional laboratory settings. It has the potential to bring sophisticated diagnostics to rural clinics, district hospitals, mobile health units, industrial locations, border regions, and other remote areas where access to centralised labs is limited.

 

In many healthcare systems, diagnostic samples are transported over long distances to centralised facilities, often causing delays and logistical challenges. Cubo addresses this gap by enabling accurate RT-PCR testing at or near the point of care, significantly reducing turnaround time and operational complexity. This aligns with the global shift toward decentralised diagnostic models and could create a strong strategic advantage for early adopters.

 

The platform features a simplified workflow and an intuitive user interface, making it accessible to physicians and healthcare providers across varied settings. Its portability and ease of use are expected to accelerate adoption compared to conventional systems that rely on extensive infrastructure and specialised environments

 

Cubo is being developed as a versatile diagnostic platform capable of supporting a wide range of assays, including tuberculosis, respiratory infections, influenza, viral panels, women’s health diagnostics, sexually transmitted infections, fever panels, and future outbreak-response applications. This broad testing capability positions it to build a strong installed base over time and emerge as a leading solution in compact, decentralised molecular diagnostics.

 

Commenting on the development, Vidhya Sagar Reddy, Managing Director of ASMS, said, “Healthcare access should not be determined by geography. Cubo represents a major step toward bringing advanced diagnostics directly into underserved markets at scale.”

 

Shesheer Kumar, Managing Director of Huwel Lifesciences, added, “Cubo has been engineered to combine scientific precision with operational simplicity. Early leadership in compact molecular diagnostics can translate into sustained long-term market strength.”